Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 14/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.82 |
| ▸ | USP2 | O75604 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ramiprilat SCHEMBL4634176 | 1.00 | ACE (0.82) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| Ramiprilat SCHEMBL9285191 | 1.00 | ACE (0.82) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| Ramiprilat SCHEMBL5490942 | 1.00 | ACE (0.82) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| Ramiprilat SCHEMBL10590419 | 1.00 | ACE (0.82) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| Ramiprilat SCHEMBL9438804 | 1.00 | ACE (0.82) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| Ramiprilat SCHEMBL5490939 | 1.00 | ACE (0.82) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| Ramiprilat SCHEMBL9594279 | 1.00 | ACE (0.82) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| Ramiprilat SCHEMBL4733176 | 1.00 | ACE (0.82) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| Ramiprilat SCHEMBL21990787 | 1.00 | ACE (0.82) | ACEMEN1KMT2ACYP3A4ALOX15 | |
| Ramiprilat SCHEMBL9438808 | 1.00 | ACE (0.82) | ACEMEN1KMT2ACYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2085 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615449-A1 | METHOD TO PREVENT AND TREAT DIABETIC RETINOPATHY BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | Weinberg, Assa (US) | 2025-09-17 | — | — | EP | claimed |
| US-20250262195-A1 | METHOD TO PREVENT AND TREAT DIABETIC RETINOPATHY BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | WEINBERG ASSA (US) | 2025-08-21 | — | — | US | claimed |
| EP-4598526-A1 | METHOD TO PREVENT AND TREAT GLAUCOMA BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | Weinberg, Assa (US) | 2025-08-13 | — | — | EP | claimed |
| US-20250228831-A1 | METHOD TO PREVENT AND TREAT GLAUCOMA BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | WEINBERG ASSA (US) | 2025-07-17 | — | — | US | claimed |
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | claimed |
| EP-4448096-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | Singapore Health Services Pte. Ltd. (SG) | 2024-10-23 | — | — | EP | claimed |
| WO-2024102328-A1 | METHOD TO PREVENT AND TREAT DIABETIC RETINOPATHY BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | WEINBERG ASSA (US) | 2024-05-16 | — | — | WO | claimed |
| WO-2024076697-A1 | METHOD TO PREVENT AND TREAT GLAUCOMA BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | WEINBERG ASSA (US) | 2024-04-11 | — | — | WO | claimed |
| EP-3474836-B1 | SALBUTAMOL-CONTAINING OPHTHALMIC MEDICAMENT | REKIK RAOUF (TN) | 2024-01-17 | — | — | EP | claimed |
| US-20230265182-A1 | USE OF IL-1 BETA BINDING ANTIBODIES TO TREAT PERIPHERAL ARTERIAL DISEASE | NOVARTIS AG (CH) | 2023-08-24 | — | — | US | claimed |
| WO-2001015673-A2 | PHARMACEUTICAL FORMULATIONS AND USE THEREOF IN THE PREVENTION OF STROKE, DIABETES AND/OR CONGESTIVE HEART FAILURE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-03-08 | — | — | WO | claimed |
| US-5977159-A | Medical use of an ace-inhibitor for treatment of dyspeptic symptoms | ASTRA AKTIEBOLAG (SE) | 1999-11-02 | — | — | US | claimed |
| CN-1207685-A | Novel medical use of ACE-inhibitor for treatment of dyspeptic symptoms | ASTRA AB (SE) | 1999-02-10 | — | — | CN | claimed |
| EP-0835123-A1 | AMINOPEPTIDASE P INHIBITORS AND USES THEREOF | LOYOLA UNIVERSITY OF CHICAGO (US) | 1998-04-15 | — | — | EP | claimed |
| EP-0804229-A2 | COMPOSITION CONTAINING AMLODIPINE, OR A SALT OR FELODIPINE AND ANACE INHIBITOR | PFIZER INC. (US) | 1997-11-05 | — | — | EP | claimed |
| EP-0795327-A1 | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin | PFIZER INC. (US) | 1997-09-17 | — | — | EP | claimed |
| US-5656603-A | INHIBITING BRANDYKININ DEGRADATION | LOYOLA UNIVERSITY OF CHICAGO (US) | 1997-08-12 | — | — | US | claimed |
| WO-1996039163-A1 | AMINOPEPTIDASE P INHIBITORS AND USES THEREOF | LOYOLA UNIVERSITY OF CHICAGO (US) | 1996-12-12 | — | — | WO | claimed |
| WO-1996028185-A2 | COMPOSITION CONTAINING AMLODIPINE, OR A SALT, OR FELODIPINE AND AN ACE INHIBITOR | PFIZER INC. (US) | 1996-09-19 | — | — | WO | claimed |
| EP-0391462-A1 | Synergistic compositions containing ketanserin | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-10-10 | — | — | EP | claimed |